JB Pharma FY26 revenue grows 6%, EBITDA up 8%

0 min read Updated on 25 May 2026, 07:08 PM

Reviewed by

Jubin VScanX News Team

AI Summary

J.B. Chemicals & Pharmaceuticals reported a 6% rise in consolidated revenue to ₹4,148 crore for FY26. EBITDA increased by 8% to ₹1,178 crore, while profit after tax rose by 8% to ₹709 crore, aided by gross margin expansion and stable costs.

*this image is generated using AI for illustrative purposes only.

J.B. Chemicals & Pharmaceuticals Limited reported a 6% increase in consolidated revenue to ₹4,148 crore for the financial year ended March 31, 2026. The company’s operating EBITDA grew by 8% to ₹1,178 crore, and profit after tax rose by 8% to ₹709 crore.

The growth was driven by a favourable product mix and stable costs, which supported gross margin expansion. On a consolidated basis, revenue stood at ₹4,14,779 lakhs, registering a 6% year-on-year growth. EBITDA margins improved to 28.4% adjusted for non-recurring items.

The domestic formulations business grew 9% to ₹24,735.4 lakhs, outperforming the Indian Pharmaceutical Market. The international business recorded revenue growth of 2% to ₹16,742.5 lakhs, supported by a healthy order pipeline in the CDMO segment.

Financial Highlights

Metric (₹ in crores)	FY26
Revenue	4,148
EBITDA	1,178
Profit After Tax	709

The board has recommended a final dividend of ₹9.30 per equity share for FY26. The interim dividend of ₹12.70 per share was paid on February 25, 2026.

Historical Stock Returns for J B Chemicals and Pharmaceuticals

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+0.22%	+5.81%	+2.20%	+24.34%	+31.45%	+193.20%

What strategies will the company employ to accelerate growth in the international business beyond the current 2% increase?

Will the favourable product mix and stable costs be sustainable enough to maintain the 28.4% EBITDA margin in the next fiscal year?

How does the company plan to utilize the healthy CDMO order pipeline to drive future revenue expansion?

Read Next Article

J.B. Chemicals fixes May 29 record date for FY26 dividend

0 min read Updated on 22 May 2026, 04:29 AM

Reviewed by

Shriram SScanX News Team

Add as a preferred
source on Google

AI Summary

J.B. Chemicals & Pharmaceuticals Limited has established May 29, 2026, as the record date to determine eligibility for the final dividend for the financial year 2025-26, in compliance with SEBI regulations. Shareholders listed in the company's records on this date will qualify for the dividend payout.

*this image is generated using AI for illustrative purposes only.

J.B. Chemicals & Pharmaceuticals Limited has fixed May 29, 2026, as the record date to determine shareholder eligibility for the final dividend for the financial year 2025-26. The announcement was made in compliance with Regulation 42 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The record date is essential for identifying the beneficial owners and shareholders entitled to receive the declared dividend. Only those shareholders listed in the company's records on this specific date will qualify for the payout.

Record Date Details

The following table outlines the key specifics regarding the corporate announcement:

Symbol	Type of Security	Record Date	Purpose
JBCHEPHARM	Equity	May 29, 2026	To ascertain eligibility of the beneficial owners/ shareholders for final dividend for financial year 2025-26.

Shareholders holding equity shares are advised to ensure their holdings are updated in the depository records to avail the dividend benefit. The company has requested the stock exchange to take this intimation on record.

Historical Stock Returns for J B Chemicals and Pharmaceuticals

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+0.22%	+5.81%	+2.20%	+24.34%	+31.45%	+193.20%

What is the expected dividend per share amount that J.B. Chemicals & Pharmaceuticals will declare for FY2025-26, and how does it compare to previous years' payouts?

How has J.B. Chemicals & Pharmaceuticals' dividend yield trended over the past five years, and what does it signal about the company's future capital allocation strategy?

Could J.B. Chemicals & Pharmaceuticals' dividend announcement influence institutional investor sentiment or trigger any changes in shareholding patterns ahead of the May 29 record date?